Page last updated: 2024-12-05
pyrovalerone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pyrovalerone: RN given refers to parent cpd; synonyms F 1983 & Centroton refer to HCl; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 14373 |
| CHEMBL ID | 201960 |
| CHEBI ID | 134998 |
| SCHEMBL ID | 164376 |
| MeSH ID | M0047465 |
Synonyms (32)
| Synonym |
|---|
| dea no. 1485 |
| pyrovalerone |
| CHEBI:134998 |
| 1-(4-methylphenyl)-2-pyrrolidin-1-ylpentan-1-one |
| CHEMBL201960 , |
| j8.659b , |
| 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one |
| bdbm50182555 |
| 1-pentanone, 1-(4-methylphenyl)-2-(1-pyrrolidinyl)- |
| pirovalerona [inn-spanish] |
| pyrovaleronum |
| vou69c02jp , |
| pyrovaleronum [inn-latin] |
| unii-vou69c02jp |
| 3563-49-3 |
| pyrovalerone [inn] |
| 4'-methyl-2-(1-pyrrolidinyl)valerophenone |
| pirovalerona |
| pyrovalerone [who-dd] |
| pyrovalerone [mi] |
| valerophenone, 4'-methyl-2-(1-pyrrolidinyl)- |
| 1-p-tolyl-1-oxo-2-pyrrolidino-n-pentane |
| pyrovalerone [mart.] |
| SCHEMBL164376 |
| 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-pentanone # |
| SWUVZKWCOBGPTH-UHFFFAOYSA-N |
| 4'-methyl-alpha-pyrrolidinovalerophenone |
| HY-U00296 |
| CS-7265 |
| Q410824 |
| DTXSID20863194 |
| 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one |
Research Excerpts
Overview
The pyrovalerone derivatives are a branch of synthetic cathinones, a very popular group of psychostimulant NPS.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The pyrovalerone derivatives are a branch of synthetic cathinones, a very popular group of psychostimulant NPS." | ( Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones. Andrzejczak, D; Wojcieszak, J; Woldan-Tambor, A; Zawilska, JB, 2016) | 1.23 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The express-method for the determination of pyrovaleron in the urine based on the combination with the method of extractive freezing-out and centrifugation of the samples as the preliminary stage of the preparation of a biological object for the analysis." | ( [The determination of pyrovaleron in the urine by gas chromatography in the combination with the method of extractive chilling-out and centrifugation]. Bekhterev, VN; Gavrilova, SN; Koshkareva, EV; Shipanov, IN, ) | 0.13 |
| " We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study." | ( Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. Feng, J; Hu, X; Jiang, Z; Li, H; Li, W; Liu, Y; Ma, F; Ouyang, Q; Tong, Z; Wang, S; Xu, B; Yu, S; Zhu, X; Zou, J, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| aromatic ketone | A ketone in which the carbonyl group is attached to an aromatic ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 (µMol) | 0.0283 | 0.0008 | 1.5416 | 20.0000 | AID261029 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 0.1950 | 0.0003 | 1.4656 | 10.0000 | AID261028 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 (µMol) | 2.7800 | 0.0001 | 0.8645 | 8.7096 | AID261027 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 3.7700 | 0.0000 | 0.7048 | 8.1930 | AID261026 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 (µMol) | 0.0420 | 0.0007 | 1.8419 | 46.0000 | AID261025; AID420092 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 0.0147 | 0.0002 | 1.1115 | 8.0280 | AID261024; AID420091 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (55)
Molecular Functions (28)
Ceullar Components (19)
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID261024 | Displacement of [125I]RTI-55 from human DAT expressed in HEK293 cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. |
| AID261025 | Inhibition of [3H] dopamine uptake into human DAT expressed in HEK293 cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. |
| AID261026 | Displacement of [125I]RTI-55 from human SERT expressed in HEK293 cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. |
| AID420092 | Inhibition of [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells by scintillation counting | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. |
| AID261029 | Inhibition of [3H] norepinephrine uptake into human NET expressed in HEK293 cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. |
| AID261027 | Inhibition of [3H] serotonin uptake into human SERT expressed in HEK293 cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. |
| AID261028 | Displacement of [125I]RTI-55 from human NET expressed in HEK293 cells | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. |
| AID420091 | Displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells by scintillation counting | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. |
| AID420093 | Ratio of IC50 for [3H]dopamine uptake at human dopamine transporter expressed in mouse N2A cells to Ki for displacement of [3H]WIN-35428 from human dopamine transporter expressed in mouse N2A cells | 2009 | Bioorganic & medicinal chemistry, Jun-01, Volume: 17, Issue:11 | A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. |
| AID493017 | Wombat Data for BeliefDocking | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 46.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (46.52) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (3.85%) | 5.53% |
| Reviews | 3 (11.54%) | 6.00% |
| Case Studies | 4 (15.38%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (69.23%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||